FDAnews Device Daily Bulletin

ACCENTIA BIOPHARMACEUTICALS LAUNCHES CRSFUNGAL PROFILE

Nov. 30, 2005
A A

Accentia Biopharmaceuticals recently announced the commercial introduction of a patented, non-invasive test, CRSFungal Profile, by its specialty pharmaceuticals division, TEAMM Pharmaceuticals, to assist in the diagnosis of Chronic Sinusitis (CS) otherwise known as Chronic Rhinosinusitis (CRS). In partnership with the licensee for this patented technology, IMMCO Diagnostics Inc. (IMMCO) of Buffalo, NY, Accentia Biopharmaceuticals is making CRSFungal Profile available to ear, nose and throat (ENT) specialists and allergists nationwide.

EurekAlert! (http://www.eurekalert.org/pub_releases/2005-11/s-abi112805.php)